Longitudinal Improvement in Waist-to-Height Ratio During SGLT-2 Inhibitor Therapy Within a Structured Multidisciplinary Care Model: A Prospective Real-World Cohort Study

Background/Objectives: The waist-to-height ratio (WHtR) is a sensitive marker of central obesity. This study examined the longitudinal trajectory of WHtR in patients with type 2 diabetes (T2DM) initiating sodium–glucose cotransporter-2 (SGLT-2) inhibitor therapy within a structured, physician-supported multidisciplinary care model. Methods: This prospective observational cohort study included 140 adults with T2DM initiating SGLT-2 inhibitor therapy, followed at a diabetes outpatient clinic by a physician, diabetes nurse, and dietitian. Anthropometric and bioimpedance measurements, physical activity, and dietary adherence were assessed at baseline, month 3, and month 6. Longitudinal changes were analyzed by repeated-measures ANOVA with Bonferroni-corrected post hoc tests, and linear mixed-effects models assessed factors associated with WHtR over time. Results: Mean age was 54.08 ± 11.40 years, and 49.3% of participants were female. WHtR decreased from 0.665 ± 0.101 at baseline to 0.635 ± 0.096 at month 3 and 0.629 ± 0.096 at month 6 (p < 0.001). Body weight (87.68 ± 18.68 to 84.18 ± 17.01 kg), BMI, and waist, hip, and neck circumferences all decreased significantly (p < 0.001), while physical activity and Mediterranean diet adherence increased (p < 0.001). In the mixed-effects model, WHtR remained significantly lower at month 3 (β = −0.029) and month 6 (β = −0.035) than at baseline (both p < 0.001) after multivariable adjustment. Female sex was associated with a higher WHtR level (β = 0.095, p < 0.001), whereas the reduction in WHtR did not differ by sex (p = 0.167). Conclusions: Initiating SGLT-2 inhibitor therapy within a structured multidisciplinary diabetes care model was associated with a significant reduction in central adiposity over six months, most notably reflected by WHtR. These findings support WHtR as a simple tool for monitoring treatment response in patients with T2DM; as mean WHtR remained above 0.5, it may also help identify patients requiring further intervention.

Authors

Institutions

Publication Details

Journal
Metabolites
Published
2026-10-26
DOI
https://doi.org/10.3390/metabo16110811
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Longitudinal Improvement in Waist-to-Height Ratio During SGLT-2 Inhibitor Therapy Within a Structured Multidisciplinary Care Model: A Prospective Real-World Cohort Study

Musa Salmanoğlu, Elif Yıldırım Ayaz, Memnune Sena Ulu, Aziz Kaan Turkoglu et al.
Metabolites
Diabetes Treatment and Management
article

Longitudinal Improvement in Waist-to-Height Ratio During SGLT-2 Inhibitor Therapy Within a Structured Multidisciplinary Care Model: A Prospective Real-World Cohort Study

Musa Salmanoğlu, Elif Yıldırım Ayaz, Memnune Sena Ulu, Aziz Kaan Turkoglu, Abdulhamid Arslan, Süleyman Kılıç
article en

Abstract

Background/Objectives: The waist-to-height ratio (WHtR) is a sensitive marker of central obesity. This study examined the longitudinal trajectory of WHtR in patients with type 2 diabetes (T2DM) initiating sodium–glucose cotransporter-2 (SGLT-2) inhibitor therapy within a structured, physician-supported multidisciplinary care model. Methods: This prospective observational cohort study included 140 adults with T2DM initiating SGLT-2 inhibitor therapy, followed at a diabetes outpatient clinic by a physician, diabetes nurse, and dietitian. Anthropometric and bioimpedance measurements, physical activity, and dietary adherence were assessed at baseline, month 3, and month 6. Longitudinal changes were analyzed by repeated-measures ANOVA with Bonferroni-corrected post hoc tests, and linear mixed-effects models assessed factors associated with WHtR over time. Results: Mean age was 54.08 ± 11.40 years, and 49.3% of participants were female. WHtR decreased from 0.665 ± 0.101 at baseline to 0.635 ± 0.096 at month 3 and 0.629 ± 0.096 at month 6 (p < 0.001). Body weight (87.68 ± 18.68 to 84.18 ± 17.01 kg), BMI, and waist, hip, and neck circumferences all decreased significantly (p < 0.001), while physical activity and Mediterranean diet adherence increased (p < 0.001). In the mixed-effects model, WHtR remained significantly lower at month 3 (β = −0.029) and month 6 (β = −0.035) than at baseline (both p < 0.001) after multivariable adjustment. Female sex was associated with a higher WHtR level (β = 0.095, p < 0.001), whereas the reduction in WHtR did not differ by sex (p = 0.167). Conclusions: Initiating SGLT-2 inhibitor therapy within a structured multidisciplinary diabetes care model was associated with a significant reduction in central adiposity over six months, most notably reflected by WHtR. These findings support WHtR as a simple tool for monitoring treatment response in patients with T2DM; as mean WHtR remained above 0.5, it may also help identify patients requiring further intervention.

MetabolitesVol. 16(11)
University of Health Science (KH), Sağlık Bilimleri Üniversitesi (TR), Universidad CES (CO), University of Health Sciences Antigua (AG)
Openalex Percentile: Top 11%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon